Literature DB >> 1922802

Fatigue and myalgia in AIDS patients.

R G Miller1, P J Carson, R S Moussavi, A T Green, A J Baker, M W Weiner.   

Abstract

Fatigue and myalgia are common in patients with acquired immunodeficiency syndrome (AIDS). To determine whether altered muscle metabolism or impaired activation of muscle might account for these symptoms, we utilized three different exercise protocols to produce fatigue in nine AIDS patients who complained of both fatigue and exercise-exacerbated myalgia. Five were taking azidothymidine (AZT), which may cause a mitochondrial myopathy. Simultaneous measures of force, EMG, and muscle metabolites (phosphocreatine, inorganic phosphate, adenosine triphosphate, and intracellular pH) using phosphorus nuclear magnetic resonance spectroscopy were performed during fatigue and recovery. There were no significant differences between patients and controls in terms of fatigability, muscle metabolism, or muscle activation. These results provide no support for the hypothesis that fatigue or myalgia in AIDS patients derives from altered muscle metabolism or that AZT produces mitochondrial myopathy.

Entities:  

Mesh:

Year:  1991        PMID: 1922802     DOI: 10.1212/wnl.41.10.1603

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Neuromuscular complications in HIV.

Authors:  Susama Verma; Elena Micsa; Lydia Estanislao; David Simpson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

2.  Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy.

Authors:  T M Sinnwell; K Sivakumar; S Soueidan; C Jay; J A Frank; A C McLaughlin; M C Dalakas
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

3.  Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.

Authors:  H Manji; M J Harrison; J M Round; D A Jones; S Connolly; C J Fowler; I Williams; I V Weller
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.